Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Silo Pharma, Inc. SILO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
21/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Silo Pharma, Inc. (SILO) is a Biotechnology company in the Healthcare sector, currently trading at $0.40. It has a SharesGrow Score of 20/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: SILO trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25).

Financials: revenue is $72,102, +0%/yr average growth. Net income is $4M (loss), growing at -3.2%/yr. Net profit margin is -5863.5% (negative). Gross margin is -1128.9% (-1220.8 pp trend).

Balance sheet: total debt is $0 against $6M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 11.36 (strong liquidity). Debt-to-assets is 0%. Total assets: $8M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

SILO SharesGrow Score Overview

36/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SILO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
30/100
SILO: +0%/yr revenue is, -3.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet SILO: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 11.36 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
SILO: Net profit margin is -5863.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.221-1.19
Volume514.83K
Avg Volume (30D)4.14M
Market Cap$3.2M
Beta (1Y)0.59
Share Statistics
EPS (TTM)-0.50
Shares Outstanding$8.38M
IPO Date2021-01-08
Employees3
CEOEric Weisblum
Financial Highlights & Ratios
Revenue (TTM)$72.1K
Gross Profit$-813.96K
EBITDA$-4.28M
Net Income$-4.23M
Operating Income$-4.28M
Total Cash$6.86M
Net Debt$-4.75M
Total Assets$7.61M
Price / Earnings (P/E)-0.8
Price / Sales (P/S)44.44
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS82711P2011

Price Chart

Track all markets on TradingView
SILO
Silo Pharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.22 52WK RANGE 1.19

People Also View

SBMFF
SBMFF
Sino Biopharmaceutical Limited
$0.76
-8.60%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 URGN
URGN
UroGen Pharma Ltd.
$21.22
+4.64%
 FBRX
FBRX
Forte Biosciences, Inc.
$32.42
+5.95%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 STTK
STTK
Shattuck Labs, Inc.
$6.78
+0.15%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message